NiTiDES: From theory to practice

Dr. R. Langhoff
Disclosure

Speaker name:
..........................................................................................

I have the following potential conflicts of interest to report:

☐ Consulting
☐ Employment in industry
☐ Stockholder of a healthcare company
☐ Owner of a healthcare company
☐ Other(s)

☒ I do not have any potential conflict of interest
Evolution of Tools for Endovascular Procedures

POBA  SES  VARIA  DES  DEB  ?
What makes a stent a Superstar?

✓ if a stent outperforms in terms of clinical and material conditions

✓ and potentially if the study nurse tells you that something is going on with an investigational device which almost never showed a restenosis during 24-month follow up
Case baseline

Patient information:
62 y old male with Claudication Rutherford III

CRF:
art. Hypertension
Smoker
Hypercholesterinemia

Duplex:
12 cm long occlusion left SFA

Access:
contralateral 6F sheath
Case angiographic findings
Case procedure:
Case procedure
ILLUMINA Case 24 months follow up

Reference (Acute result)
Conclusions

- Drug-elution has proven benefits on clinical outcomes in SFA treatment over non-drug based treatment
- PTX-gate is still ongoing and safety concerns exist
- Amphilimus™ (Sirolimus + fatty acid) is a drug with proven outcomes in a daily practice scenario
- NiTiDES showed superb 24 month-data for a SFA DES strategy with the lowest TLR rate ever
- We now have a drug-based and stent based approach, even without a toxic PTX effect on the vessel wall
NiTiDES: From theory to practice

Dr. R. Langhoff